Brokerages expect Ingevity Corp (NYSE:NGVT) to post sales of $264.90 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ingevity’s earnings. The lowest sales estimate is $260.00 million and the highest is $269.80 million. Ingevity reported sales of $229.50 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 19th.
According to Zacks, analysts expect that Ingevity will report full-year sales of $1.12 billion for the current year, with estimates ranging from $1.11 billion to $1.12 billion. For the next year, analysts expect that the company will post sales of $1.23 billion, with estimates ranging from $1.22 billion to $1.26 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Ingevity.
Ingevity (NYSE:NGVT) last issued its quarterly earnings results on Wednesday, October 24th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.12. Ingevity had a return on equity of 47.45% and a net margin of 15.53%. The company had revenue of $311.20 million for the quarter, compared to analyst estimates of $305.50 million.
Shares of NGVT traded down $5.58 during midday trading on Friday, hitting $95.02. The company’s stock had a trading volume of 180,404 shares, compared to its average volume of 201,378. Ingevity has a one year low of $66.57 and a one year high of $106.59. The company has a debt-to-equity ratio of 2.31, a quick ratio of 1.26 and a current ratio of 2.34. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of 36.83, a PEG ratio of 2.18 and a beta of 1.48.
Hedge funds have recently modified their holdings of the stock. Advisors Preferred LLC acquired a new position in Ingevity during the 3rd quarter worth about $120,000. Harvest Fund Management Co. Ltd acquired a new position in Ingevity during the 3rd quarter worth about $134,000. Synovus Financial Corp lifted its stake in shares of Ingevity by 961.5% in the 2nd quarter. Synovus Financial Corp now owns 1,380 shares of the company’s stock valued at $112,000 after purchasing an additional 1,250 shares during the period. Signaturefd LLC lifted its stake in shares of Ingevity by 211.9% in the 3rd quarter. Signaturefd LLC now owns 1,472 shares of the company’s stock valued at $150,000 after purchasing an additional 1,000 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new position in shares of Ingevity in the 2nd quarter valued at about $146,000. Institutional investors and hedge funds own 92.89% of the company’s stock.
Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells wood-based chemically activated carbon products primarily for gasoline vapor emission control systems.
Further Reading: Compound Interest and Why It Matters When Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.